Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...
المؤلفون الرئيسيون: | Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
2014
|
مواد مشابهة
-
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
حسب: Ruiz Garcia, V, وآخرون
منشور في: (2011) -
Certolizumab pegol in therapy for rheumatoid arthritis
حسب: Galina Viktorovna Lukina, وآخرون
منشور في: (2012-06-01) -
Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
حسب: M Connock, وآخرون
منشور في: (2010-10-01) -
QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
حسب: Vera Nikolayevna Amirdjanova, وآخرون
منشور في: (2012-10-01) -
New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
حسب: Evgeniy L'vovich Nasonov, وآخرون
منشور في: (2011-02-01)